+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis

Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis

Arthritis and Rheumatism 44(9): 2024-2028

To examine matrix metalloproteinase 9 (MMP-9) in the synovial fluid (SF) and synovial membrane (SM) in relation to vascular endothelial cell (EC) apoptosis, vascular endothelial growth factor (VEGF), and SM vascular pattern. Thirty-four patients underwent needle arthroscopy of the knee joint; 12 had early rheumatoid arthritis (RA), 12 had early psoriatic arthritis (PsA), and 10 had osteoarthritis (OA). The early RA and early PsA patients were matched for disease activity. SF levels of MMP-9 and VEGF were measured by an enzyme-linked immunosorbent assay, and EC apoptosis was measured by TUNEL assay. MMP-9 expression was examined in SM by immunohistochemistry. Synovial tissue explants were stimulated with VEGF, and MMP-9 levels were measured in the supernatants. The synovial vascular pattern was recorded. SF MMP-9 levels were significantly higher in early PsA patients than in early RA patients; OA patients had minimal levels. MMP-9 levels correlated with blood vessel morphology and SF VEGF levels. MMP-9 expression was greater in early PsA SM than in early RA SM, but the difference was not significant. In contrast however, EC apoptosis was greater in early RA SM than in early PsA SM. MMP-9 levels increased 2-fold and 9-fold, respectively, in SM explant culture supernatants on day 7 in response to stimulation with 25 ng/ml and 50 ng/ml of VEGF. SF MMP-9 levels correlate with the pattern of SM neovascularization and SF VEGF levels in early inflammatory arthritis, and VEGF increases MMP-9 production by SM. Endothelial cell apoptosis, however, appears to be more prevalent in early RA. This combination of factors may explain the pattern of differential angiogenesis in these arthritides.

(PDF emailed within 0-6 h: $19.90)

Accession: 046631171

Download citation: RISBibTeXText

PMID: 11592363

DOI: 10.1002/1529-0131(200109)44:9<2024::aid-art351>3.0.co;2-k

Related references

Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis and Rheumatism 44(10): 2263-2274, 2001

Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Research & Therapy 11(6): R161-R161, 2010

Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arthritis and Rheumatism 63(12): 3824-3832, 2012

Early diagnosis of rheumatoid arthritis in collagen-induced arthritis mice using fluorogenic matrix metalloproteinase-3-specific polymeric probe. 2011

Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. Arthritis and Rheumatism 56(9): 2864-2874, 2007

In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis. Arthritis & Rheumatology 66(3): 589-598, 2014

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. British Journal of Rheumatology 36(6): 643-650, 1997

Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95(9): 1963-1970, 2002

Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma. Journal of Neurotrauma 33(1): 65-70, 2016

Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor. World Journal of Gastroenterology 11(32): 5032-5036, 2005

Factor-Xa cleaves secreted pro-matrix metalloproteinase-2 and releases active matrix metalloproteinase-2 from human vascular smooth muscle cells. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Supplement 1): R99, March, 2002

Rhinovirus upregulates matrix metalloproteinase-2, matrix metalloproteinase-9, and vascular endothelial growth factor expression in nasal polyp fibroblasts. Laryngoscope 119(9): 1834-1838, 2010

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal 150(3): 484-487, 2005

Expression of matrix metalloproteinase-2,matrix metalloproteinase-9 and vascular endothdial growth factor in retinoblastoma and its clinical significance. Yan Ke Xue Bao 25(1): 62-64, 2016

Serum amyloid A and matrix metalloproteinase production in early arthritis. British Journal of Rheumatology 36(SUPPL 1): 94, 1997